Patient characteristics of CALBG50303 parent study vs CALBG 580603 imaging substudy
| . | Imaging substudy (N = 158) . | Parent study only (N = 333) . | Total (N = 491) . | P . |
|---|---|---|---|---|
| Age (y) | .595 | |||
| Mean (SD) | 55.6 (13.9) | 56.3 (15.1) | 56.1 (14.7) | |
| Q1, Q3 | 48, 66 | 47, 67 | 47, 67 | |
| Range | 20-82 | 18-86 | 18-86 | |
| Sex | .812 | |||
| Female | 71 (44.9%) | 155 (46.5%) | 226 (46%) | |
| Male | 87 (55.1%) | 178 (53.5%) | 265 (54%) | |
| ECOG | .635 | |||
| 0 | 66 (41.8%) | 149 (44.7%) | 215 (43.8%) | |
| 1 | 74 (46.8%) | 141 (42.3%) | 215 (43.8%) | |
| 2 | 18 (11.4%) | 43 (12.9%) | 61 (12.4%) | |
| Extranodal status | .222 | |||
| N-missing | 2 | 2 | 4 | |
| No | 115 (73.7%) | 262 (79.2%) | 377 (77.4%) | |
| Yes | 41 (26.3%) | 69 (20.8%) | 110 (22.6%) | |
| Stage | .913 | |||
| N-missing | 6 | 9 | 15 | |
| Stage I primary mediastinal | 3 (1.97%) | 10 (3.09%) | 13 (2.73%) | |
| Stage II de novo CD20 DLBCL | 31 (20.4%) | 68 (21%) | 99 (20.8%) | |
| Stage III de novo CD20 DLBCL | 42 (27.6%) | 88 (27.2%) | 130 (27.3%) | |
| Stage IV de novo CD20 DLBCL | 76 (50%) | 158 (48.8%) | 234 (49.2%) | |
| IPI | .374 | |||
| N-Missing | 7 | 8 | 15 | |
| Low risk | 46 (30.5%) | 77 (23.7%) | 123 (25.8%) | |
| Low-intermediate risk | 49 (32.5%) | 127 (39.1%) | 176 (37%) | |
| High-intermediate risk | 39 (25.8%) | 82 (25.2%) | 121 (25.4%) | |
| High risk | 17 (11.3%) | 39 (12%) | 56 (11.8%) | |
| Treatment | .569 | |||
| Dose-adjusted etoposide, prednisone, oncovin (vincristine), cyclophosphamide, hydroxydaunorubicin, rituximab | 81 (51.3%) | 160 (48%) | 241 (49.1%) | |
| R-CHOP | 77 (48.7%) | 173 (52%) | 250 (50.9%) |
| . | Imaging substudy (N = 158) . | Parent study only (N = 333) . | Total (N = 491) . | P . |
|---|---|---|---|---|
| Age (y) | .595 | |||
| Mean (SD) | 55.6 (13.9) | 56.3 (15.1) | 56.1 (14.7) | |
| Q1, Q3 | 48, 66 | 47, 67 | 47, 67 | |
| Range | 20-82 | 18-86 | 18-86 | |
| Sex | .812 | |||
| Female | 71 (44.9%) | 155 (46.5%) | 226 (46%) | |
| Male | 87 (55.1%) | 178 (53.5%) | 265 (54%) | |
| ECOG | .635 | |||
| 0 | 66 (41.8%) | 149 (44.7%) | 215 (43.8%) | |
| 1 | 74 (46.8%) | 141 (42.3%) | 215 (43.8%) | |
| 2 | 18 (11.4%) | 43 (12.9%) | 61 (12.4%) | |
| Extranodal status | .222 | |||
| N-missing | 2 | 2 | 4 | |
| No | 115 (73.7%) | 262 (79.2%) | 377 (77.4%) | |
| Yes | 41 (26.3%) | 69 (20.8%) | 110 (22.6%) | |
| Stage | .913 | |||
| N-missing | 6 | 9 | 15 | |
| Stage I primary mediastinal | 3 (1.97%) | 10 (3.09%) | 13 (2.73%) | |
| Stage II de novo CD20 DLBCL | 31 (20.4%) | 68 (21%) | 99 (20.8%) | |
| Stage III de novo CD20 DLBCL | 42 (27.6%) | 88 (27.2%) | 130 (27.3%) | |
| Stage IV de novo CD20 DLBCL | 76 (50%) | 158 (48.8%) | 234 (49.2%) | |
| IPI | .374 | |||
| N-Missing | 7 | 8 | 15 | |
| Low risk | 46 (30.5%) | 77 (23.7%) | 123 (25.8%) | |
| Low-intermediate risk | 49 (32.5%) | 127 (39.1%) | 176 (37%) | |
| High-intermediate risk | 39 (25.8%) | 82 (25.2%) | 121 (25.4%) | |
| High risk | 17 (11.3%) | 39 (12%) | 56 (11.8%) | |
| Treatment | .569 | |||
| Dose-adjusted etoposide, prednisone, oncovin (vincristine), cyclophosphamide, hydroxydaunorubicin, rituximab | 81 (51.3%) | 160 (48%) | 241 (49.1%) | |
| R-CHOP | 77 (48.7%) | 173 (52%) | 250 (50.9%) |
ECOG, Eastern Cooperative Oncology Group; SD, standard deviation.